139 related articles for article (PubMed ID: 15777246)
21. Glia proinflammatory cytokine upregulation as a therapeutic target for neurodegenerative diseases: function-based and target-based discovery approaches.
Van Eldik LJ; Thompson WL; Ralay Ranaivo H; Behanna HA; Martin Watterson D
Int Rev Neurobiol; 2007; 82():277-96. PubMed ID: 17678967
[TBL] [Abstract][Full Text] [Related]
22. Interferon-γ plays a role in paraquat-induced neurodegeneration involving oxidative and proinflammatory pathways.
Mangano EN; Litteljohn D; So R; Nelson E; Peters S; Bethune C; Bobyn J; Hayley S
Neurobiol Aging; 2012 Jul; 33(7):1411-26. PubMed ID: 21482445
[TBL] [Abstract][Full Text] [Related]
23. Brain serotonin transporter binding in non-depressed patients with Parkinson's disease.
Guttman M; Boileau I; Warsh J; Saint-Cyr JA; Ginovart N; McCluskey T; Houle S; Wilson A; Mundo E; Rusjan P; Meyer J; Kish SJ
Eur J Neurol; 2007 May; 14(5):523-8. PubMed ID: 17437611
[TBL] [Abstract][Full Text] [Related]
24. Stress and cytokine-elicited neuroendocrine and neurotransmitter sensitization: implications for depressive illness.
Hayley S; Merali Z; Anisman H
Stress; 2003 Mar; 6(1):19-32. PubMed ID: 12637204
[TBL] [Abstract][Full Text] [Related]
25. Metal-catalyzed disruption of membrane protein and lipid signaling in the pathogenesis of neurodegenerative disorders.
Mattson MP
Ann N Y Acad Sci; 2004 Mar; 1012():37-50. PubMed ID: 15105254
[TBL] [Abstract][Full Text] [Related]
26. Cytokine toxicity to oligodendrocyte precursors is mediated by iron.
Zhang X; Haaf M; Todorich B; Grosstephan E; Schieremberg H; Surguladze N; Connor JR
Glia; 2005 Nov; 52(3):199-208. PubMed ID: 15968631
[TBL] [Abstract][Full Text] [Related]
27. Biochemistry of Parkinson's disease: is a brain serotonergic deficiency a characteristic of idiopathic Parkinson's disease?
Kish SJ
Adv Neurol; 2003; 91():39-49. PubMed ID: 12442662
[No Abstract] [Full Text] [Related]
28. Cholesterol involvement in the pathogenesis of neurodegenerative diseases.
Liu JP; Tang Y; Zhou S; Toh BH; McLean C; Li H
Mol Cell Neurosci; 2010 Jan; 43(1):33-42. PubMed ID: 19660552
[TBL] [Abstract][Full Text] [Related]
29. Olfactory dysfunction in Parkinson's disease.
Wszolek ZK; Markopoulou K
Clin Neurosci; 1998; 5(2):94-101. PubMed ID: 10785834
[TBL] [Abstract][Full Text] [Related]
30. Dynamic changes in pro- and anti-inflammatory cytokines in microglia after PPAR-γ agonist neuroprotective treatment in the MPTPp mouse model of progressive Parkinson's disease.
Pisanu A; Lecca D; Mulas G; Wardas J; Simbula G; Spiga S; Carta AR
Neurobiol Dis; 2014 Nov; 71():280-91. PubMed ID: 25134730
[TBL] [Abstract][Full Text] [Related]
31. Depressive disorders in Parkinson's disease may be due to a shared immune-mediated neurodegenerative process.
Kummer A; Teixeira AL
Med Hypotheses; 2008; 70(1):201-2. PubMed ID: 17881136
[No Abstract] [Full Text] [Related]
32. Recent progress in neurodegenerative disorder research in China.
Zhou J
Sci China Life Sci; 2010 Mar; 53(3):348-355. PubMed ID: 20596930
[TBL] [Abstract][Full Text] [Related]
33. Microglial phagocytosis is enhanced by monomeric alpha-synuclein, not aggregated alpha-synuclein: implications for Parkinson's disease.
Park JY; Paik SR; Jou I; Park SM
Glia; 2008 Aug; 56(11):1215-23. PubMed ID: 18449945
[TBL] [Abstract][Full Text] [Related]
34. NCAM in neuropsychiatric and neurodegenerative disorders.
Brennaman LH; Maness PF
Adv Exp Med Biol; 2010; 663():299-317. PubMed ID: 20017030
[No Abstract] [Full Text] [Related]
35. Central administration of murine interferon-α induces depressive-like behavioral, brain cytokine and neurochemical alterations in mice: a mini-review and original experiments.
Hayley S; Scharf J; Anisman H
Brain Behav Immun; 2013 Jul; 31():115-27. PubMed ID: 22884959
[TBL] [Abstract][Full Text] [Related]
36. Immunomodulation of Parkinson's disease using Mucuna pruriens (Mp).
Rai SN; Birla H; Zahra W; Singh SS; Singh SP
J Chem Neuroanat; 2017 Nov; 85():27-35. PubMed ID: 28642128
[TBL] [Abstract][Full Text] [Related]
37. Acorus gramineus inhibits microglia mediated neuroinflammation and prevents neurotoxicity in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced mouse model of Parkinson's disease.
Jiang J; Kim JJ; Kim DY; Kim MK; Oh NH; Koppula S; Park PJ; Choi DK; Shin YK; Kim IH; Kang TB; Lee KH
J Ethnopharmacol; 2012 Dec; 144(3):506-13. PubMed ID: 23085397
[TBL] [Abstract][Full Text] [Related]
38. Stress, immunity, cytokines and depression.
Anisman H
Acta Neuropsychiatr; 2002 Dec; 14(6):251-61. PubMed ID: 26984573
[TBL] [Abstract][Full Text] [Related]
39. Hippocampal-prefrontal circuit and disrupted functional connectivity in psychiatric and neurodegenerative disorders.
Li M; Long C; Yang L
Biomed Res Int; 2015; 2015():810548. PubMed ID: 25918722
[TBL] [Abstract][Full Text] [Related]
40. Inflammatory mechanisms of neurodegeneration in toxin-based models of Parkinson's disease.
Litteljohn D; Mangano E; Clarke M; Bobyn J; Moloney K; Hayley S
Parkinsons Dis; 2010 Dec; 2011():713517. PubMed ID: 21234362
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
